Medrx Co

Medrx Co EBIT Growth

The Year-over-Year EBIT Growth of Medrx Co (4586.T) as of Nov 19, 2026 is -17.67 %. In the previous year, Year-over-Year EBIT Growth was 14.25 % — a change of -224.01% (lower).

EBIT Growth

-17.67 %

YoY

-224.01%

Last updated:

Year-over-Year EBIT Growth of Medrx Co is 2025 -17.67 % . Year-over-Year EBIT Growth of Medrx Co was 2024 14.25 % . It decreases by -224.01% lower compared to the previous year.

The Medrx Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-25.12 JPY
Jan 1, 2019
-27.85 JPY
Jan 1, 2020
30.56 JPY
Jan 1, 2021
6.12 JPY
Jan 1, 2022
-4.36 JPY
Jan 1, 2023
15.70 JPY
Jan 1, 2024
14.25 JPY
Jan 1, 2025
-17.67 JPY
The Medrx Co EBIT Growth history
YEAREBIT GrowthYoY
-17.67 %-224.01%
14.25 %-9.23%
15.70 %-460.48%
-4.36 %-171.16%
6.12 %-79.97%
30.56 %-209.75%
-27.85 %+10.86%
-25.12 %-203.77%
24.21 %-170.62%
-34.28 %-10,741.18%
0.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Year-over-Year EBIT Growth of Medrx Co is -17.67 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Medrx Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Medrx Co

All Key Metrics — Medrx Co